Abstract:BACKGROUND: Alzheimer's disease (AD) is the most common type of dementia and mainly treated by drugs, while the therapeutic outcomes are very limited. This study aimed to determine the optimized parameters of deep brain stimulation (DBS) which was applied to the treatment of AD and propose the involved mechanisms.METHODS: Amyloid-β precursor protein/Presenilin1 (APP/PS1) transgenic mice were used and received DBS at nucleus basalis of Meynert (NBM). The optimized parameters of DBS were determined by using different stimulation frequencies, durations and ages of mice under Morris water maze test. The involved mechanisms and the possible signal pathways were also investigated.RESULTS: The optimized parameters for DBS were high frequency (100 Hz) for 21 days starting from early age (4 months old). Under the above parameters, the soluble Aβ40 and Aβ42 in the hippocampus and cortex were down-regulated significantly. DBS increased survival neurons and reduced apoptotic cells in the hippocampus and cortex. Meanwhile, the apoptosis-related proteins caspase-3, caspase-8 and Bid were down-regulated. Moreover, DBS caused a significant increase of superoxide dismutase, glutathione peroxidase and choline acetyltransferase activity as well as a decrease of methane dicarboxylic aldehyde content and acetylcholine esterase activity. Phosphorylation of Akt (p-Akt)/total Akt (t-Akt) was up-regulated while p-extracellular signal-regulated kinase 1/2 (ERK1/2)/t-ERK1/2 was down-regulated. The neuroprotective effect of DBS was attenuated by their inhibitors.CONCLUSIONS: NBM-DBS starting from 4 months of age for 21 days at a high frequency (100 Hz) has therapeutic effects on AD through activating phosphatidylinositol 3'-kinase (PI3K)/Akt pathway and inhibiting ERK1/2 pathway.

Corrigendum to “the Neuroprotective Effect of Deep Brain Stimulation at Nucleus Basalis of Meynert in Transgenic Mice with Alzheimer’s Disease” [brain Stimul 12 (2019) 161–174]

The neuroprotective effect of deep brain stimulation at nucleus basalis of Meynert in transgenic mice with Alzheimer's disease

Correction to: Inhibition of Dectin-1 Ameliorates Neuroinflammation by Regulating Microglia/Macrophage Phenotype After Intracerebral Hemorrhage in Mice

Author Correction: Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice

Corrigendum to “neuroprotective Effect of Nicorandil Through Inhibition of Apoptosis by the PI3K/Akt1 Pathway in a Mouse Model of Deep Hypothermic Low Flow” [journal of the Neurological Sciences Volume 357, Issues 1–2, 15 October 2015, Pages 119–125]

Corrigendum to “Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice” [Bioactive materials 6 (2021) 529–542]

Author Correction: Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Author Correction: Single-cell transcriptomic analysis of Alzheimer’s disease

Correction: Corrigendum: Opportunities and challenges in modeling human brain disorders in transgenic primates

Corrigendum: Using Transcranial Direct Current Stimulation to Augment the Effect of Motor Imagery-Assisted Brain-Computer Interface Training in Chronic Stroke Patients—Cortical Reorganization Considerations

Chronic deep brain stimulation in an Alzheimer's disease mouse model enhances memory and reduces pathological hallmarks

Corrigendum to “central Angiotensin II‐induced Alzheimer‐like Tau Phosphorylation in Normal Rat Brains” [FEBS Lett. 586 (2012) 3737–3745]

Corrigendum: Mechanisms of mitophagy and oxidative stress in cerebral ischemia–reperfusion, vascular dementia, and Alzheimer's disease

Author Correction: Reversing a model of Parkinson’s disease with in situ converted nigral neurons

Correction: Shibly et al. Analysis of Cerebral Small Vessel Changes in AD Model Mice. Biomedicines 2023, 11, 50

Corrigendum: Efficacy of non-invasive brain stimulation for disorders of consciousness: a systematic review and meta-analysis

Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy: Erratum

Correction: Dominguez-Meijide et al. Pharmacological Modulators of Tau Aggregation and Spreading. Brain Sci. 2020, 10, 858

Author Correction: C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

A circuit view of deep brain stimulation in Alzheimer’s disease and the possible mechanisms

Retraction Note to: Effects of BDNF-Transfected BMSCs on Neural Functional Recovery and Synaptophysin Expression in Rats with Cerebral Infarction